EFFICIENCY OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION AND OBESITY DEPENDING ON THE POLYMORPHISM OF CYP2C9 GENE

Aim. To assess the efficiency of combined antihypertensive therapy in patients with arterial hypertension and obesity depending on the polymorphism of CYP2C9 gene.

Materials and methods. Patients with uncontrolled arterial hypertension (1-2 stage) and obesity were included in our study. They were randomized by the method of "converts" into two groups: the first group (n=70) took the fixed-dose combinations of the valsartan and amlodipine and the second group took the fixed-dose combinations of the perindopril and amlodipine. Blood pressure of all patients was measured according to the recommendation for diagnosis and treatment of arterial hypertension (ESH/ESC, 2013) before and after 8 weeks of the initial treatment. All tested people had venous blood sampling succeeded by DNA extraction and amplification in real time mode polymorphic variants CYP2C9 gene. The improvement of health self-esteem by QALY was determined like increase of index from initial by 10 % and more.

Results. It is shown that people with heterozygosis polymorphisms *1/*2 and *1/*3 reached the target level of arterial blood pressure after 8 weeks of combined therapy of valsartan and the amlodipine (93,1% against 57,1% respectively). In addition to the above, the frequency of reaching the target level of the arterial blood pressure in the group of tested people who get angiotensin II receptor blocker and calcium-channel blocker was for certain higher among the patients with polymorphisms *1/*2 and *1/*3 in comparison with the polymorphic variants CYP2C9 gene (91,3% against 57,1% respectively). The improvement of the health self-esteem by QALY of the tested patients with polymorphisms *1/*2 and *1/*3 CYP2C9 gene is seen more often between the patients of the first group than between patients of the second group (95,6% against 66,7% respectively).

Conclusion. Determined interrelation between the efficiency level of the combined antihypertensive therapy with the CYP2C9 gene polymorphism can be considered in cases of insufficient effect of assigned therapy or the uncontrolled character of the arterial hypertension. In our opinion, appropriate personalized correction of therapy will contribute to its optimization relating to the patients with arterial hypertension and obesity.

1. Boytsov S.A., Deev A.D., Shalnova S.A. Mortality and risk factors for noncommunicable diseases in Russia: Specific features, trends, and prognosis. Therapeutic Archive. 2017; 89(1): 5-13. (In Russ.) DOI:10.17116/terarkh20178915-13.

2. Boytsov S.A., Balanova Yu. A., Shalnova S.A. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014; 13(4): 4-14. (In Russ.).

3. Chazova I.E., Zhernakova Yu.V., Oshchepkova E.V., Yarovaya E.B., Konradi A.O. et al. Prevalence of cardiovascular diseases risk factors in Russian population of patients with arterial hypertension. Cardiology. 2014; 54(10): 4-12. (In Russ.) DOI: https://dx.doi.org/10.18565/cardio.2014.10.4-12.

4. Mancia G., Fagard R., Narkiewicz K., et al.2013 ESH/ESC Guidelines for the management of arterial hypertension/ The Task Force for the managment of arterial hypertension of the Europian Society of Hypertension (ESH) and the Europian Society of Cardiology (ESC). J. Hypertens. 2013; 31: 1281-357.

5. Brady T.M. The Role of Obessity in the Development of Left Ventricular Hypertropht Among Children and Adolescents. Curr Hypertens Rep. 2016; 18(1): 3-11. DOI: 10.1007/s11906-015-0608-3.

6. Chazova I.E., Fomin V.V., Razuvaeva M.A., Vigdorchik A.V. Epidemiological characteristics of resistant and uncontrolled arterial hypertension in the Russian Federation (Russian Register of uncontrolled and resistant arterial hypertension – REGATA-PRIMA). Systemic Hypertensions. 2010; 3: 34-41. (In Russ.).

7. Diagnosis and treatment of arterial hypertension. Russian recommendations (Fourth Review). Systematic hypertensions. 2010; 3: 5-26.

8. Shirley M., McCormack P.L. Perindopril/amlodipine (Prestalia(®)): a review in hypertension. Am J Cardiovasc Drugs. 2015; 15(5): 363-70. DOI: 10.1007/s40256-015-0144-1.

9. Sison J., Assaad-Khalil S.H., Najem R., et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/ valsartan/hydrochlorothiazide in hypertension: the EXCITE study. Curr Med Res Opin. 2014; 30(10): 1937-45. DOI: 10.1185/03007995.

10. Cabaleiro T., Román M., Ochoa D. Evaluation of the Relationship between Sex, Polymorphisms in CYP2C8 and CYP2C9, and Pharmacokinetics of Angiotensin Receptor Blockers. Drug Metabolism and Disposition. 2013; 41(1): 224-229. DOI: 10.1124/dmd.112.046292.

11. Yang R., Luo Z., Liu Y. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450. Curr Drug Metab. 2016; 17(7): 681-91. DOI: 10.2174/138920021766616052 4143843.

12. Guo G., Zhao Y., Chai J. Effectiveness evaluation of cardiovascular drugs based on CYP2C9 target protein. Pak J Pharm Sci. 2015; 28(4): 1545-9.

13. Tsarukyan A.A., Baturin V.A., Bobryshev D.V. Prevalence of polymorphic variants CYP2C9*2 and CYP2C9*3 gene of cytochrome in some ethnic groups of Stavropol region’s dwellers. Molecule diagnostics. 2017; 1: 517-518.

14. Yagudina R.I., Kulikov A. Yu., Litvinenko M.M. QALY: history, methodology and the method’s future. Pharmacoeconomics. 2010; 3(1): 11-14.

15. Rosemary J., Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Cur. Clin. Pharmacol. 2007; 2: 93-109. DOI: 10.2174/157488407779422302

16. Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem. 2003; 46: 2261-2270. DOI: 10.1021/jm0204237.

17. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other antihypertensives. Drug Saf. 2003; 26: 707-720.

18. Leonova M.V. Clinical pharmacology of angiotensin II receptor blockers: valsartan. Medicinskiy sovet. 2014; 17: 66-71.

19. Sanderson S. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 2005; 7(2): 97-104. DOI: 10.109701.GIM.0000153664.65759.CF